HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $88
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $72 to $88.
HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $72 to $88.